Emergent facility to work on TB, typhoid vaccines
Emergent BioSolutions plans to renovate a 55,000-square-foot facility. The facility isn't slated to open until 2012; however, upon its completion, the expansion will not only give Emergent more space to fill government contracts for BioThrax, but also will allow the developer to start testing commercial vaccines for ailments like tuberculosis and typhoid. Report
Editor's Note: Article modified to remove "in Baltimore" from first sentence.